Robert Koch and the discovery of the tubercle bacillus: The challenge of HIV and tuberculosis 125 years later

International Journal of Tuberculosis and Lung Disease

Volumn 12, Issue 3, 2008, Pages 241-249

  Harries, A D ^a,b,c  

^a MINISTRY OF HEALTH   (Malawi)

^b FAMILY HEALTH INTERNATIONAL   (United States)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

HIV AIDS; Robert Koch; TB; TB control

Indexed keywords

ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; COTRIMOXAZOLE; EFAVIRENZ; FANSIDAR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTEGRASE INHIBITOR; ISONIAZID; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR;

HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; COMORBIDITY; DIRECTLY OBSERVED THERAPY; DISEASE MANAGEMENT; GERMANY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HIV INFECTIONS; HUMANS; MALAWI; PREVALENCE; TUBERCULOSIS, PULMONARY;

EID: 40549094651     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Daniel T M. Robert Koch and the pathogenesis of tuberculosis. Int J Tuberc Lung Dis 2005; 9: 1181-1182.
2. Kaufmann S H E. Robert Koch, the Nobel Prize, and the ongoing threat of tuberculosis. N Engl J Med 2005; 353: 2423-2428.
3. Roberts C A, Buikstra J E. The history of tuberculosis from earliest times to the development of drugs. In: Davies P D O, ed. Clinical tuberculosis. 3rd ed. London, UK: Arnold, 2003.
4. Harries A D, Dye C. Tuberculosis. Ann Trop Med Parasitology 2006; 100: 415-431.
5. Epstein H. The invisible cure. Africa, the West, and the fight against AIDS. New York, NY, USA: Farrar, Strauss and Giroux, 2007.
6. Pneumocystis pneumonia - Los Angeles. MMWR Morb Mortal Wkly Rep 1981; 30: 250-252.
7. UNAIDS and the World Health Organization. AIDS epidemic update. December 2006. UNAIDS/WHO, 2006.
8. Merson M H. The HIV-AIDS pandemic at 25 - the global response. N Engl J Med 2006; 354: 2414-2417.
9. Bean P. New drug targets for HIV. Clin Infect Dis 2005; 41 (Suppl): S96-S100.
10. Dye C, Scheele S, Dolin P, Pathania V, Raviglione M C. Global burden of tuberculosis: estimated incidence, prevalence and mortality by country. JAMA 1999; 282: 677-686.
11. Sutherland I. Recent studies in the epidemiology of tuberculosis, based on the risk of being infected with tubercle bacilli. Adv Tuberc Res 1976; 19: 1-63.
12. Sonnenberg P, Glynn J R, Fielding K, Murray J, Godfrey-Faussett P, Shearer S. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis 2005; 191: 150-158.
13. Corbett E L, Watt C J, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Int Med 2003; 163: 1009-1021.
14. World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO report 2007. WHO/HTM/TB/2007.376. Geneva, Switzerland: WHO, 2007.
15. Kochi A. The global tuberculosis situation and the new control strategy of the World Health Organization. Tubercle 1991; 72: 1-6.
16. World Health Organization. Global tuberculosis programme. Framework for effective tuberculosis control. WHO/TB/94.179. Geneva, Switzerland: WHO, 1994.
17. World Health Organization. Treatment of tuberculosis. Guidelines for national programmes. WHO/CDS/TB 2003.313. Geneva, Switzerland: WHO, 2003.
18. World Health Organization. Fifty-third World Health Assembly. Stop TB Initiative, report by the director-general. A53/5, 5 May 2000. Resolution WHA53.1. Geneva, Switzerland: WHO, 2000.
19. Styblo K, Bumgarner J R. Tuberculosis can be controlled with existing technologies: evidence. TSRU Progress Report 1991; 2: 60-72.
20. Nunn P, Williams B, Floyd K, Dye C, Elzinga G, Raviglione M. Tuberculosis control in the era of HIV. Nature Rev 2005; 5: 819-826.
21. Harries A D, Hargreaves N J, Gausi F, Kwanjana J H, Salaniponi F M. High death rates in health care workers and teachers in Malawi. Trans Roy Soc Trop Med Hyg 2002; 96: 34-37.
22. Salaniponi F M L, Kwanjana J, Nyasulu I, et al. Loss of tuberculosis officers from a national tuberculosis programme: the Malawi experience. Int J Tuberc Lung Dis 1999; 3: 174-175.
23. Colebunders R, Bastian I. A review of the diagnosis and treatment of smear-negative pulmonary tuberculosis. Int J Tuberc Lung Dis 2000; 4: 97-107.
24. Greenberg S D, Frager D, Suster B, Walker S, Stavropoulos C, Rothpearl A. Active pulmonary tuberculosis in patients with AIDS: spectrum of radiographic findings (including a normal appearance). Radiology 1994; 193: 115-119.
25. Hargreaves N J, Kadzakumanja O, Phiri S, et al. What causes smear-negative pulmonary tuberculosis in Malawi, an area of high HIV seroprevalence? Int J Tuberc Lung Dis 2001; 5: 113-122.
26. Lucas S B, de Cock K M, Hounnou A, et al. Contribution of tuberculosis to slim disease in Africa. BMJ 1994; 308: 1531-1533.
27. Harries A D, Hargreaves N J, Kemp J, et al. Deaths from tuberculosis in sub-Saharan African countries with a high prevalence of HIV-1. Lancet 2001; 357: 1519-1523.
28. Korenromp E L, Scano F, Williams B G, Dye C, Nunn P. Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampicin-based treatment: an analytic review. Clin Infect Dis 2003; 37: 101-112.
29. Gandhi N R, Moll A, Sturm W, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368: 1575-1580.
30. Raviglione M C. The Global Plan to Stop TB, 2006-2015. Int J Tuberc Lung Dis 2006; 10: 238-239.
31. World Health Organization Stop TB Partnership. The Global Plan to Stop TB 2006-2015. Geneva, Switzerland: WHO, 2006.
32. World Health Organization. Interim policy on collaborative TB/HIV activities. Stop TB Department and Department of HIV/AIDS. WHO/HTM/TB/2004.330. Geneva, Switzerland: WHO, 2004.
33. World Health Organization. Guidelines for the prevention of tuberculosis in health care facilities in resource-limited settings. WHO/TB/99.269. Geneva, Switzerland: WHO, 1999.
34. World Health Organization. Report of a 'lessons learnt' workshop on the six PROTEST pilot projects in Malawi, South Africa and Zambia. WHO/HTM/TB/2004.336. Geneva, Switzerland: WHO, 2004.
35. Lawn S D, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 2005; 19: 2109-2116.
36. The Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration and ART Cohort Collaboration (ART-CC) groups. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367: 817-824.
37. Lawn S D, Myer L, Orrell C, Bekker L-G, Wood R. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS 2005; 19: 2141-2148.
38. Wilkinson D, Squire S B, Garner P. Effect of preventive treatment for tuberculosis in adults infected with HIV: systematic review of randomised placebo controlled trials. BMJ 1998; 317: 625-629.
39. Fitzgerald D W, Desvarieux M, Severe P, Joseph P, Johnson W D, Pape J W. Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial. Lancet 2000; 356: 1470-1474.
40. Churchyard G J, Fielding K, Charalambous S, et al. Efficacy of secondary isoniazid preventive therapy among HIV-infected southern Africans: time to change policy? AIDS 2003; 17: 1-8.
41. World Health Organization. TB-HIV update, November 2007. Geneva, Switzerland: WHO, 2007.
42. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002; 359: 2059-2064.
43. Lawn S D, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 2005; 19: 2109-2116.
44. Golub J E, Saraceni V, Cavalcante S C, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2007; 21: 1441-1448.
45. Zachariah R, Massaquoi M. Cotrimoxazole prophylaxis for HIV-positive TB patients in developing countries. Trop Doct 2006; 36: 79-82.
46. Renaud-Thery F, Nguimfack B D, Vitoria M, et al. Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens. AIDS 2007; 21 (Suppl 4): S89-S95.
47. World Health Organization. Antiretroviral therapy of HIV infection in adults and adolescents in resource-limited settings, towards universal access. Recommendations for a public health approach. Geneva, Switzerland: WHO, 2006.
48. Swaminathan S, Luetkemeyer A, Srikantiah P, Lin R, Havlir D. Antiretroviral therapy and TB. Trop Doct 2006; 36: 73-79.
49. Zachariah R, Fitzgerald M, Massaquoi M, et al. Does antiretroviral treatment reduce case fatality among HIV-positive patients with tuberculosis in Malawi? Int J Tuberc Lung Dis 2007; 11: 848-853.
50. Harries A D, Chimzizi R, Zachariah R. Safety, effectiveness, and outcomes of concomitant use of highly active antiretroviral therapy with drugs for tuberculosis in resource-poor settings. Lancet 2006; 367: 944-945.
51. Chen L, Evans T, Anand S, et al. Human resources for health: overcoming the crisis. Lancet 2004; 364: 1984-1990.